Research programme: NOX2 activators - ProNoxis

Drug Profile

Research programme: NOX2 activators - ProNoxis

Latest Information Update: 07 Aug 2016

Price : $50

At a glance

  • Originator ProNoxis
  • Class Small molecules
  • Mechanism of Action NADPH oxidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Guillain-Barre syndrome; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 07 Aug 2016 Preclinical trials in Inflammatory bowel disease in Sweden (PO)
  • 07 Aug 2016 Preclinical trials in Systemic lupus erythematosus in Sweden (PO)
  • 07 Aug 2016 Preclinical trials in Guillain-Barre syndrome in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top